IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Goldberg, J. In re Application of Examiner: Sai P. Sunkara Art Unit: 1614 Serial No.: 09/160,977 Filed: **September 25, 1998** I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on Method of Treating Cancer by Title: Conjunctive Therapy with 2'-Halomethylidene Derivatives and a S-Phase or M-Phase Specific **Antineoplastic Agent** 1600 MAIL ROOM PETITION FOR EXTENSION OF TIME **Assistant Commissioner for Patents** Washington, D.C. 20231 Sir: Applicant(s) request that the time for taking action in this case be extended pursuant to 37 C.F.R. 1.136(a) for: one month (\$110) three months (\$870) five months (\$1850) \Box two months (\$380) \bowtie four months (\$1360) The fee set in 37 C.F.R. 1.17 for the extension is \$1360. months has already been secured and the fee paid therefor of \$ An extension for is deducted from the total fee due to the total months of extension now requested. Therefore, the extension fee due with this request is \$ The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 and 1.17 which may be required by this paper, or credit any overpayment to Account No. 13-2764. Two duplicate copies of this sheet are enclosed. Also enclosed is a Appeal Brief Response Notice of Appeal Respectfully submitted, 04/05/2000 MBERHE 00000090 132764 09160977 01 FC:118 1360.00 CH Mark C. Nelligan, Reg. No. 36,389 Attorney/Agent for Applicant Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800

Docket No. MO1660J US

Telefax

Telephone (908) 231-2388

(908) 231-2626